Nov 15, 2024 9:47 am EST OS Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update
Oct 30, 2024 8:51 am EDT Join OS Therapies’ Exclusive Live Investor Webinar and Q&A Session on October 30
Oct 28, 2024 4:44 pm EDT OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors
Oct 17, 2024 9:22 am EDT OS Therapies to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
Oct 03, 2024 8:00 am EDT OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Completes Last Patient Visit
Sep 13, 2024 8:09 am EDT OS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate (tADC)-Based Therapeutic Candidates
Sep 11, 2024 8:15 am EDT OS Therapies Announces Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Developed Based on Tunable Antibody Drug Conjugate (tADC) Platform Using Proprietary Silicone Linker Platform in Preclinical Models